NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”), of the important October 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...

NEW YORK, Sept. 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”), of the important October 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...

NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 14, 2025. SO WHAT: If you purchased Unicycive securities dur ...

NEW YORK, Sept. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 14, 2025. SO WHAT: If you purchased Unicycive securities dur ...

诉讼案件基本情况 - 罗森律师事务所代表在2024年3月29日至2025年6月27日期间购买Unicycive Therapeutics Inc (NASDAQ: UNCY)证券的投资者提起集体诉讼 [1] - 投资者可通过应急费用安排获得补偿而无需支付任何自付费用 [2] - 投资者若希望担任首席原告需在2025年10月14日前向法院提出动议 [1][3] 诉讼指控内容 - 被告被指控在Unicycive满足FDA生产合规要求的能力方面存在虚假和/或误导性陈述 [5] - 被告被指控夸大了氧碳酸镧(OLC)新药申请(NDA)的监管前景 [5] - 这些虚假陈述导致投资者在市场了解真相后遭受损失 [5] 律师事务所背景 - 罗森律师事务所专注于证券集体诉讼和股东派生诉讼 [4] - 该所曾创下对中国公司最大证券集体诉讼和解记录 [4] - 2017年被ISS证券集体诉讼服务评为证券集体诉讼和解数量第一名 [4] - 自2013年以来每年排名前四 已为投资者追回数亿美元 [4] - 2019年单独为投资者获得超过4.38亿美元赔偿 [4]

公司诉讼事件 - 罗森律师事务所宣布代表在2024年3月29日至2025年6月27日期间购买Unicycive Therapeutics公司(NASDAQ: UNCY)证券的股东提起集体诉讼 [1] - 诉讼指控公司存在虚假和/或误导性陈述 未能披露其过度夸大满足FDA生产合规要求的能力以及过度夸大氧化镧碳酸盐新药申请的监管前景 [2][3] - 诉讼声称当真相公开后 投资者遭受了损失 [3] 公司背景 - Unicycive Therapeutics是一家处于临床阶段的生物技术公司 [1] - 公司主要业务涉及氧化镧碳酸盐新药申请 [3] 法律程序 - 股东需在2025年10月14日前向法院申请担任首席原告 [4] - 律师事务所采用风险代理收费模式 股东无需支付任何费用或开支 [5] - 罗森律师事务所自成立以来已为股东追回超过10亿美元损失 [6] 行业动态 - 生物技术行业面临监管合规风险 [3] - 律师事务所专门处理投资者权利诉讼案件 [6]